What is the best strategy after initial treatment with hypomethylating agents for high grade myelodysplatic syndromes, mainly for responders who became transfusion independent?

Topics: Hematologic Malignancies • Medical Oncology • Myelodysplastic Syndromes • Leukemia • Hematology

Do we continue the hypomethylating agent indefinitely?

Answer from: Medical Oncologist at Academic Institution

The hypomethylating agents (HMAâ€™s, 5-azacitidine & decitabine) have important disease modifying properties in addition to relieving cytopenias for patients with high-risk MDS. They decrease the risk of progression to leukemia and improve overall survival. The randomized phase I...

Related Questions